{"entity":{"id":"paper-joseph-perioperative-nsclc-cost-effectiveness-sri-lanka-bmjonc-2026","kind":"paper","name":"Cost-effectiveness of perioperative novel therapies for stage II to III non-small cell lung cancer in Sri Lanka","aka":[],"tldr":"At a threshold of US$6,700 per quality-adjusted life year, adjuvant osimertinib, adjuvant alectinib and neoadjuvant nivolumab were cost-effective in Sri Lanka; at US$3,000 only the osimertinib strategies remained so.","summary":"A Markov cost-utility model from the Sri Lankan health system's perspective compared adjuvant, neoadjuvant, perioperative and consolidation targeted and immunotherapies for stage II to III NSCLC, with sex-specific analyses, a lifetime horizon and a 5-year budget impact for the therapies found cost-effective.","asOf":"2026-11-11","links":[{"label":"BMJ Oncology 2026","url":"https://doi.org/10.1136/bmjonc-2025-001046"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/42369562/"}],"tags":[],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["sri-lanka-ministry-of-health"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"journal":"BMJ Oncology","year":2026,"doi":"10.1136/bmjonc-2025-001046","pmid":"42369562","authors":"Joseph N, Kularatna S, Senanayake S.","paperType":"methods","findings":["At US$6,700 per QALY, adjuvant osimertinib after surgery and after curative chemoradiotherapy, adjuvant alectinib after surgery and neoadjuvant nivolumab were cost-effective in both men and women.","At US$3,000 per QALY, only osimertinib-based strategies remained robustly cost-effective; the other therapies would need substantial price reductions.","The 5-year budget impact of adopting the cost-effective therapies under full implementation was about US$11.8 million."],"whatItMeans":"A worked example of how the free state system could rank costly lung cancer drugs and what price cuts would bring others within reach.","caveats":["Model-based; conclusions were sensitive to lower, opportunity-cost-informed thresholds."]},"route":"/key-papers/paper-joseph-perioperative-nsclc-cost-effectiveness-sri-lanka-bmjonc-2026/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"institution":[{"id":"sri-lanka-ministry-of-health","kind":"institution","name":"Ministry of Health and Mass Media, Sri Lanka","route":"/institutions/sri-lanka-ministry-of-health/"}]}}